Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
62 hedge funds and large institutions have $338M invested in Akcea Therapeutics Inc in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 14 closing their positions.
9% less funds holding
Funds holding: 68 → 62 (-6)
25% less call options, than puts
Call options by funds: $4.38M | Put options by funds: $5.84M
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
39% less capital invested
Capital invested by funds: $554M → $338M (-$216M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.31M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.21M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$616K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.32M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.88M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1M |
AKCA Hedge Fund Activity: Q3 2019 in Review
62 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q3 2019, worth a combined $338M — down 39% from $554M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AKCA and 8 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 16 added.
The largest buyer was Vanguard Group, adding an estimated $2.13M. The largest seller was Fidelity Investments, cutting an estimated $19.2M.
- 62 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q3 2019, down from 68 in Q2 2019.
- Funds reported $338M of Akcea Therapeutics Inc stock for Q3 2019, down 39% quarter-over-quarter.
- 8 funds opened new Akcea Therapeutics Inc positions in Q3 2019 and 14 closed out, a net change of -6 holders.
- The largest Akcea Therapeutics Inc buyer in Q3 2019 was Vanguard Group, an estimated $2.13M added.
- The largest Akcea Therapeutics Inc seller in Q3 2019 was Fidelity Investments, an estimated $19.2M sold.
Based on aggregated 13F filings for Q3 2019.